Anatara Confirms Safety and Encouraging Subgroup Trends in GaRP-IBS Phase II Trial Review

Anatara Lifesciences Ltd (ASX: ANR) has completed a detailed internal review of the GaRP-IBS Phase II trial data following headline results released in April 2025. The trial’s primary safety endpoint was met, with no treatment-related adverse events observed in the 78-participant. Although a statistically significant reduction in the IBS Severity Scoring System (IBS-SSS) versus placebo was not achieved, the treatment group experienced a 40% reduction from baseline, exceeding the secondary endpoint threshold of 20%.

Notably, statistically significant improvements were recorded in anxiety scores at Week 8 (p=0.034), contributing to an overall significant HADS score improvement (p=0.025). Subgroup analyses suggested symptom relief in pain and abdominal distension, with no marked differences across gender or IBS subtypes. These findings and the project’s strong preclinical IBD foundation will support upcoming commercialization efforts. Anatara’s anti-obesity preclinical program remains on track for further progress within six months.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com